Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07PQJ
|
|||
| Former ID |
DIB002747
|
|||
| Drug Name |
ARQ-087
|
|||
| Indication | Intrahepatic cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1; ICD-9: 155.1, 156.1] | Phase 3 | [1] | |
| Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 2 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [3] | ||
| Company |
ArQule Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H29FN4O
|
|||
| Canonical SMILES |
COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
|
|||
| InChI |
1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
|
|||
| InChIKey |
KPJDVVCDVBFRMU-AREMUKBSSA-N
|
|||
| CAS Number |
CAS 1234356-69-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01752920) Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.